Natera, Inc. $NTRA Shares Sold by Van ECK Associates Corp

Van ECK Associates Corp lowered its position in shares of Natera, Inc. (NASDAQ:NTRA - Free Report) by 11.0% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 74,780 shares of the medical research company's stock after selling 9,262 shares during the period. Van ECK Associates Corp owned approximately 0.05% of Natera worth $20,299,000 as of its most recent SEC filing.

Other institutional investors have also made changes to their positions in the company. JPMorgan Chase & Co. grew its holdings in Natera by 10.5% during the 4th quarter. JPMorgan Chase & Co. now owns 12,854,334 shares of the medical research company's stock valued at $2,944,800,000 after purchasing an additional 1,225,420 shares in the last quarter. BlackRock Inc. acquired a new position in Natera in the 2nd quarter worth $2,962,770,000. Wellington Management Group LLP boosted its position in Natera by 94.7% in the 4th quarter. Wellington Management Group LLP now owns 4,976,325 shares of the medical research company's stock valued at $1,140,026,000 after buying an additional 2,420,263 shares during the last quarter. State Street Corp grew its stake in shares of Natera by 2.2% during the third quarter. State Street Corp now owns 3,389,599 shares of the medical research company's stock valued at $545,624,000 after acquiring an additional 72,087 shares in the last quarter. Finally, Coatue Management LLC increased its position in shares of Natera by 1,446.1% during the fourth quarter. Coatue Management LLC now owns 2,633,334 shares of the medical research company's stock worth $603,270,000 after acquiring an additional 2,463,008 shares during the last quarter. 99.90% of the stock is owned by institutional investors and hedge funds.

Natera Stock Performance

Shares of NASDAQ:NTRA opened at $326.26 on Monday. The company's fifty day moving average is $285.07 and its two-hundred day moving average is $233.78. Natera, Inc. has a 1-year low of $157.43 and a 1-year high of $343.18. The stock has a market capitalization of $47.03 billion, a price-to-earnings ratio of -239.90 and a beta of 1.51.

Natera (NASDAQ:NTRA - Get Free Report) last posted its quarterly earnings results on Thursday, August 6th. The medical research company reported ($0.47) EPS for the quarter, beating the consensus estimate of ($0.49) by $0.02. The business had revenue of $752.75 million during the quarter, compared to analyst estimates of $661.24 million. Natera had a negative net margin of 7.11% and a negative return on equity of 11.38%. The company's quarterly revenue was up 37.7% on a year-over-year basis. During the same period in the previous year, the business posted ($0.74) EPS. Sell-side analysts expect that Natera, Inc. will post -1.02 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

NTRA has been the subject of a number of analyst reports. Piper Sandler increased their price target on Natera from $249.00 to $363.50 and gave the company an "overweight" rating in a report on Wednesday, August 12th. Sanford C. Bernstein started coverage on Natera in a research note on Friday, June 26th. They set an "outperform" rating and a $310.00 target price for the company. TD Cowen upped their price target on shares of Natera from $325.00 to $340.00 and gave the company a "buy" rating in a report on Friday, August 7th. Wells Fargo & Company raised their price objective on shares of Natera from $220.00 to $284.00 and gave the stock an "equal weight" rating in a report on Friday, August 7th. Finally, The Goldman Sachs Group started coverage on shares of Natera in a research note on Friday, June 5th. They issued a "neutral" rating and a $245.00 target price on the stock. Two analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Natera has a consensus rating of "Moderate Buy" and a consensus target price of $319.38.

Insider Buying and Selling

In other news, Director Herm Rosenman sold 16,530 shares of the company's stock in a transaction that occurred on Wednesday, June 24th. The stock was sold at an average price of $250.00, for a total transaction of $4,132,500.00. Following the completion of the transaction, the director directly owned 4,250 shares of the company's stock, valued at approximately $1,062,500. This represents a 79.55% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Gail Boxer Marcus sold 11,000 shares of the company's stock in a transaction that occurred on Friday, June 5th. The shares were sold at an average price of $217.21, for a total value of $2,389,310.00. Following the transaction, the director directly owned 6,183 shares of the company's stock, valued at $1,343,009.43. This trade represents a 64.02% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 103,472 shares of company stock valued at $24,960,134 over the last 90 days. 5.05% of the stock is owned by corporate insiders.

Natera Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.

Want to see what other hedge funds are holding NTRA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Natera, Inc. (NASDAQ:NTRA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source